Undervalued Small Caps With Insider Action On ASX In November 2024

In recent weeks, the Australian market has demonstrated resilience, with the ASX200 reaching new highs despite mixed performances across various sectors. While Health Care and Financials have shown strength, Energy and Industrials have lagged behind, highlighting a diverse landscape for investors to navigate. In this context, identifying small-cap stocks with potential insider action can offer unique opportunities for those seeking growth in an evolving market environment.

Top 10 Undervalued Small Caps With Insider Buying In Australia

Name	PE	PS	Discount to Fair Value	Value Rating
GWA Group	15.9x	1.5x	42.58%	★★★★★★
DUG Technology	53.9x	2.3x	49.40%	★★★★★☆
Collins Foods	18.3x	0.7x	3.16%	★★★★☆☆
Dicker Data	18.8x	0.7x	-56.10%	★★★★☆☆
Eureka Group Holdings	18.8x	6.0x	26.79%	★★★★☆☆
FINEOS Corporation Holdings	NA	3.4x	47.93%	★★★★☆☆
Healius	NA	0.6x	11.05%	★★★★☆☆
Tabcorp Holdings	NA	0.5x	7.44%	★★★★☆☆
Corporate Travel Management	24.1x	2.9x	40.90%	★★★☆☆☆
Cromwell Property Group	NA	4.5x	-17.12%	★★★☆☆☆

Click here to see the full list of 28 stocks from our Undervalued ASX Small Caps With Insider Buying screener.

Let's explore several standout options from the results in the screener.

Healius (ASX:HLS)

Simply Wall St Value Rating: ★★★★☆☆

Overview: Healius is a healthcare company primarily engaged in providing pathology and imaging services, with a market capitalization of A$2.36 billion.

Operations: Healius generates revenue primarily from its Pathology and Imaging segments, contributing A$1.27 billion and A$474.5 million, respectively. The company's gross profit margin has shown a declining trend, reaching 31.00% by the end of 2024. Operating expenses have consistently impacted profitability, with significant non-operating expenses further affecting net income margins negatively over recent periods.

PE: -1.6x

Healius, a smaller player in Australia's healthcare sector, presents an intriguing case for investors seeking overlooked opportunities. Despite recent shareholder dilution and reliance on external borrowing, the company's earnings are projected to soar by 85% annually. Insider confidence is evident with recent share purchases throughout 2024. The sale of Lumus Imaging in September 2024 highlights strategic repositioning efforts. With constitutional amendments approved in November 2024, Healius is poised for potential transformation amidst industry shifts.

• Delve into the full analysis valuation report here for a deeper understanding of Healius.

• Understand Healius' track record by examining our Past report.

Infomedia (ASX:IFM)

Simply Wall St Value Rating: ★★★★★★

Overview: Infomedia is a company that specializes in providing software solutions and data analytics for the automotive industry, with a market capitalization of A$0.45 billion.

Operations: The revenue model primarily revolves around publishing periodicals, with recent revenues reaching A$140.83 million. Operating expenses are significant, driven by general and administrative costs, which recently amounted to A$74.38 million. The net income margin has shown a decreasing trend over time but recently improved to 9.01%.

PE: 40.6x

Infomedia, a dynamic player in the Australian market, is eyeing mergers and acquisitions to bolster long-term shareholder value. Despite facing challenges from one-off financial impacts and reliance on external borrowing, the company's earnings are projected to grow by 21% annually. Recent insider confidence is evident as they increase their holdings, suggesting optimism about future prospects. With strategic leadership changes like Joe Powell's board appointment and active capital management plans, Infomedia seems poised for potential growth despite its funding risks.

• Click here to discover the nuances of Infomedia with our detailed analytical valuation report.

• Assess Infomedia's past performance with our detailed historical performance reports.

Qualitas (ASX:QAL)

Simply Wall St Value Rating: ★★★☆☆☆

Overview: Qualitas is a company engaged in direct lending and funds management, with a market cap of A$1.13 billion.

Operations: The company generates revenue primarily from Direct Lending and Funds Management. Over recent periods, it has experienced a consistent gross profit margin of approximately 100%. Operating expenses are mainly driven by general and administrative costs, with non-operating expenses also playing a significant role.

PE: 28.6x

Qualitas, an Australian company with a market cap under A$1 billion, is drawing attention for its potential value. Recent insider confidence is evident as they purchased shares between September and November 2024, signaling belief in the company's future. Despite relying solely on external borrowing for funding, which carries more risk than customer deposits, Qualitas forecasts earnings growth of 22% annually. Recent board changes include Darren Steinberg's appointment and Brian Delaney's retirement, potentially influencing strategic direction.

• Dive into the specifics of Qualitas here with our thorough valuation report.

• Evaluate Qualitas' historical performance by accessing our past performance report.

Taking Advantage

• Discover the full array of 28 Undervalued ASX Small Caps With Insider Buying right here.
• Hold shares in these firms? Setup your portfolio in Simply Wall St to seamlessly track your investments and receive personalized updates on your portfolio's performance.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Contemplating Other Strategies?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com